Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rg3 and TACE in Notch1-high Hepatocellular Carcinoma
NCT02724358Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Dec 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ginsenoside Rg3 in hepatocellular carcinoma (HCC), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Overall Survival at 3 years. Started Dec 2012; status: completed.
02
Drugs
ginsenoside Rg3
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02724358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724358.